Equillium Q3 net loss $13.7M ($0.40/shr); Metacrine deal to add $35M cash

Equillium, Inc.

2022-Q3 EPS reported -$1.95

Net loss $13.7M ($0.40/shr) vs $10.3M ($0.35) in Q3 2021; R&D $8.8M, G&A $4.5M.
Cash, equivalents and investments $44.5M as of Sep 30; pending Metacrine acquisition expected to add ~$35M cash, extending runway into 2024.
Positive interim itolizumab data in lupus nephritis: 83% achieved complete or partial response by week 28; 67% had >80% UPCR reduction.
Initiated Phase 2 study of EQ101 in alopecia areata (30 subjects) and Phase 1 study of EQ102 in celiac disease; data expected in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Equillium, Inc. reported the third quarter ended September 30, 2022 results: net income $13.7 million, EPS $(0.40) per basic and diluted share.

Period: the third quarter ended September 30, 2022
Net income: $13.7 million
EPS: $(0.40) per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2022 was $13.7 million, or $(0.40) per basic and diluted share, compared with a net loss of $10.3 million, or $(0.35) per basic and diluted share for the same period in 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.